The aim of the present report is to present an experience with 125 febrile neutropenic patients to examine therapeutic guidelines and to determine the efficacy of treatments, in an attempt to determine the evolution of predictive risk factors. Febrile neutropenia still remains the major cause of morbi-mortality in patiens with chemotherapic-related neutropenia, mainly due to the recent more agressive antineoplastic therapy. We retrospectively studied since March 1993 and propectively between August 1994 and April 1995, 125 patients with neutrophil counts of less than 1.000 and with an axillary temperature of 38° or with signs and symptoms of infectious foci. The results obtained are presented and discussed.
|Number of pages||4|
|Journal||Prensa Medica Argentina|
|State||Published - Dec 1 1996|
ASJC Scopus subject areas